Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells.

Peeters MJW, Dulkeviciute D, Draghi A, Ritter C, Rahbech A, Skadborg SK, Seremet T, Carnaz Simões AM, Martinenaite E, Halldórsdóttir HR, Andersen MH, Olofsson GH, Svane IM, Rasmussen LJ, Met Ö, Becker JC, Donia M, Desler C, Thor Straten P.

Cancer Immunol Res. 2019 Sep;7(9):1472-1484. doi: 10.1158/2326-6066.CIR-18-0841. Epub 2019 Jul 2.

PMID:
31266785
2.

Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1270. doi: 10.1074/mcp.W119.001571. No abstract available.

3.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1255-1268. doi: 10.1074/mcp.RA119.001524.

PMID:
31154438
4.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
5.

Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model.

Idorn M, Skadborg SK, Kellermann L, Halldórsdóttir HR, Holmen Olofsson G, Met Ö, Thor Straten P.

Oncoimmunology. 2018 Apr 18;7(8):e1450715. doi: 10.1080/2162402X.2018.1450715. eCollection 2018.

6.

Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site.

Idorn M, Thor Straten P.

Cells. 2018 Aug 17;7(8). pii: E108. doi: 10.3390/cells7080108. Review.

7.

Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity.

Mathiesen CBK, Carlsson MC, Brand S, Möller SR, Idorn M, Thor Straten P, Pedersen AE, Dabelsteen S, Halim A, Würtzen PA, Brimnes J, Ipsen H, Petersen BL, Wandall HH.

J Allergy Clin Immunol. 2018 Dec;142(6):1983-1987. doi: 10.1016/j.jaci.2018.07.030. Epub 2018 Aug 17. No abstract available.

PMID:
30125661
8.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2018 Nov;17(11):2132-2145. doi: 10.1074/mcp.RA118.000792. Epub 2018 Aug 2. Retraction in: Mol Cell Proteomics. 2019 Jun;18(6):1270.

PMID:
30072578
9.

Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction.

Idorn M, Olsen M, Halldórsdóttir HR, Skadborg SK, Pedersen M, Høgdall C, Høgdall E, Met Ö, Thor Straten P.

Oncoimmunology. 2017 Dec 26;7(4):e1412029. doi: 10.1080/2162402X.2017.1412029. eCollection 2018.

10.

Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.

Rius C, Attaf M, Tungatt K, Bianchi V, Legut M, Bovay A, Donia M, Thor Straten P, Peakman M, Svane IM, Ott S, Connor T, Szomolay B, Dolton G, Sewell AK.

J Immunol. 2018 Apr 1;200(7):2263-2279. doi: 10.4049/jimmunol.1700242. Epub 2018 Feb 26.

11.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

12.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Holmström MO, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L, Riley CH, Thor Straten P, Svane IM, Hasselbalch HC, Andersen MH.

Leukemia. 2018 Feb;32(2):429-437. doi: 10.1038/leu.2017.214. Epub 2017 Jul 5.

PMID:
28676668
13.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM.

Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27.

14.

Exercise and cancer: from "healthy" to "therapeutic"?

Idorn M, Thor Straten P.

Cancer Immunol Immunother. 2017 May;66(5):667-671. doi: 10.1007/s00262-017-1985-z. Epub 2017 Mar 21. Review.

15.

(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation.

Køllgaard T, Kornblit B, Petersen J, Klausen TW, Mortensen BK, Brændstrup P, Sengeløv H, Høgdall E, Müller K, Vindeløv L, Andersen MH, Thor Straten P.

PLoS One. 2016 Dec 20;11(12):e0168210. doi: 10.1371/journal.pone.0168210. eCollection 2016.

16.

mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met Ö, Hansen M, Andersen MH, Thor Straten P, Svane IM.

Oncoimmunology. 2016 Jul 8;5(9):e1207842. eCollection 2016.

17.

"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.

Maio M, Bertocci E, Fazio C, Chiarucci C, Cutaia O, Scala E, Giacobini G, Lofiego MF, Fonsatti E, Maccalli C, Nicolay HJ, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2016 Nov;65(11):1423-1431. Epub 2016 Sep 12. No abstract available.

PMID:
27619513
18.

Exercise: A new role for an old tool.

Idorn M, Thor Straten P.

Mol Cell Oncol. 2016 Apr 15;3(4):e1163005. doi: 10.1080/23723556.2016.1163005. eCollection 2016 Jul.

19.

Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.

Idorn M, Thor Straten P, Svane IM, Met Ö.

Methods Mol Biol. 2016;1428:261-76. doi: 10.1007/978-1-4939-3625-0_17.

PMID:
27236805
20.

Targetless T cells in cancer immunotherapy.

Thor Straten P, Garrido F.

J Immunother Cancer. 2016 Apr 19;4:23. doi: 10.1186/s40425-016-0127-z. eCollection 2016.

21.

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö, Andersen MH, Thor Straten P, Svane IM.

Clin Cancer Res. 2016 Aug 1;22(15):3734-45. doi: 10.1158/1078-0432.CCR-15-1879. Epub 2016 Mar 22.

22.

Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution.

Pedersen L, Idorn M, Olofsson GH, Lauenborg B, Nookaew I, Hansen RH, Johannesen HH, Becker JC, Pedersen KS, Dethlefsen C, Nielsen J, Gehl J, Pedersen BK, Thor Straten P, Hojman P.

Cell Metab. 2016 Mar 8;23(3):554-62. doi: 10.1016/j.cmet.2016.01.011. Epub 2016 Feb 16.

23.

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.

Donia M, Andersen R, Kjeldsen JW, Fagone P, Munir S, Nicoletti F, Andersen MH, Thor Straten P, Svane IM.

Cancer Res. 2015 Sep 15;75(18):3747-59. doi: 10.1158/0008-5472.CAN-14-2956. Epub 2015 Jul 16.

24.

Design and validation of conditional ligands for HLA-B*08:01, HLA-B*15:01, HLA-B*35:01, and HLA-B*44:05.

Frøsig TM, Yap J, Seremet T, Lyngaa R, Svane IM, Thor Straten P, Heemskerk MH, Grotenbreg GM, Hadrup SR.

Cytometry A. 2015 Oct;87(10):967-75. doi: 10.1002/cyto.a.22689. Epub 2015 Jun 1.

25.

Broadening the repertoire of melanoma-associated T-cell epitopes.

Frøsig TM, Lyngaa R, Met Ö, Larsen SK, Donia M, Svane IM, Thor Straten P, Hadrup SR.

Cancer Immunol Immunother. 2015 May;64(5):609-20. doi: 10.1007/s00262-015-1664-x. Epub 2015 Feb 18.

26.

Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.

Gouttefangeas C, Chan C, Attig S, Køllgaard TT, Rammensee HG, Stevanović S, Wernet D, thor Straten P, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM.

Cancer Immunol Immunother. 2015 May;64(5):585-98. doi: 10.1007/s00262-014-1649-1. Epub 2015 Feb 18.

27.

Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease.

Pedersen M, Andersen R, Nørgaard P, Jacobsen S, Thielsen P, Thor Straten P, Svane IM.

Cancer Immunol Immunother. 2014 Dec;63(12):1341-6. doi: 10.1007/s00262-014-1607-y. Epub 2014 Sep 17.

PMID:
25227926
28.

Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.

Idorn M, Køllgaard T, Kongsted P, Sengeløv L, Thor Straten P.

Cancer Immunol Immunother. 2014 Nov;63(11):1177-87. doi: 10.1007/s00262-014-1591-2. Epub 2014 Aug 2.

PMID:
25085000
29.

T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.

Lyngaa R, Pedersen NW, Schrama D, Thrue CA, Ibrani D, Met O, Thor Straten P, Nghiem P, Becker JC, Hadrup SR.

Clin Cancer Res. 2014 Apr 1;20(7):1768-78. doi: 10.1158/1078-0432.CCR-13-2697. Epub 2014 Feb 13.

30.

Self-reactive T cells: suppressing the suppressors.

Becker JC, thor Straten P, Andersen MH.

Cancer Immunol Immunother. 2014 Apr;63(4):313-9. doi: 10.1007/s00262-013-1512-9. Epub 2013 Dec 25. Review.

PMID:
24368340
31.

Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes.

Sittig SP, Køllgaard T, Grønbæk K, Idorn M, Hennenlotter J, Stenzl A, Gouttefangeas C, Thor Straten P.

Oncoimmunology. 2013 Sep 1;2(9):e26014. Epub 2013 Sep 26.

32.

Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.

Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B, Thor Straten P, Mellemgaard A, Andersen MH, Svane IM.

Clin Cancer Res. 2014 Jan 1;20(1):221-32. doi: 10.1158/1078-0432.CCR-13-1560. Epub 2013 Nov 11.

33.

High frequency of T cells specific for cryptic epitopes in melanoma patients.

Andersen RS, Andersen SR, Hjortsø MD, Lyngaa R, Idorn M, Køllgård TM, Met O, Thor Straten P, Hadrup SR.

Oncoimmunology. 2013 Jul 1;2(7):e25374.

34.

Immune-suppressive properties of the tumor microenvironment.

Becker JC, Andersen MH, Schrama D, Thor Straten P.

Cancer Immunol Immunother. 2013 Jul;62(7):1137-48. doi: 10.1007/s00262-013-1434-6. Epub 2013 May 11. Review.

PMID:
23666510
35.

Effector CD4 and CD8 T cells and their role in the tumor microenvironment.

Hadrup S, Donia M, Thor Straten P.

Cancer Microenviron. 2013 Aug;6(2):123-33. doi: 10.1007/s12307-012-0127-6. Epub 2012 Dec 16.

36.

Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy.

Hansen M, Hjortø GM, Donia M, Met Ö, Larsen NB, Andersen MH, thor Straten P, Svane IM.

Vaccine. 2013 Jan 11;31(4):639-46. doi: 10.1016/j.vaccine.2012.11.053. Epub 2012 Nov 29.

PMID:
23200882
37.

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.

Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met Ö, Hölmich LR, Andersen RS, Hadrup SR, Andersen MH, thor Straten P, Svane IM.

J Transl Med. 2012 Aug 21;10:169. doi: 10.1186/1479-5876-10-169.

38.

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.

Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, Li YF, Robbins PF, Besser MJ, Schachter J, Kenter GG, Dudley ME, Rosenberg SA, Haanen JB, Hadrup SR, Schumacher TN.

Oncoimmunology. 2012 Jul 1;1(4):409-418.

39.

Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.

Becker JC, Andersen MH, Hofmeister-Müller V, Wobser M, Frey L, Sandig C, Walter S, Singh-Jasuja H, Kämpgen E, Opitz A, Zapatka M, Bröcker EB, Thor Straten P, Schrama D, Ugurel S.

Cancer Immunol Immunother. 2012 Nov;61(11):2091-103. doi: 10.1007/s00262-012-1266-9. Epub 2012 May 8.

40.

Dissection of T-cell antigen specificity in human melanoma.

Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, Ellebæk E, Svane IM, Schumacher TN, Thor Straten P, Hadrup SR.

Cancer Res. 2012 Apr 1;72(7):1642-50. doi: 10.1158/0008-5472.CAN-11-2614. Epub 2012 Feb 6.

41.

Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.

Brimnes MK, Gang AO, Donia M, Thor Straten P, Svane IM, Hadrup SR.

Cancer Immunol Immunother. 2012 Aug;61(8):1221-31. doi: 10.1007/s00262-011-1199-8. Epub 2012 Jan 12.

PMID:
22237888
42.

Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application.

Junker N, Thor Straten P, Andersen MH, Svane IM.

J Skin Cancer. 2011;2011:574695. doi: 10.1155/2011/574695. Epub 2011 Jun 18.

43.

A potential role of indoleamine 2,3-dioxygenase-specific T cells in leishmania vaccination.

thor Straten P, Andersen MH.

J Infect Dis. 2011 Aug 1;204(3):488-9. doi: 10.1093/infdis/jir274. Epub 2011 Jul 8. No abstract available.

44.

Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2.

Bjoern J, Brimnes MK, Andersen MH, Thor Straten P, Svane IM.

Scand J Immunol. 2011 Mar;73(3):222-33. doi: 10.1111/j.1365-3083.2010.02494.x.

45.

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

Sørensen RB, Hadrup SR, Svane IM, Hjortsø MC, Thor Straten P, Andersen MH.

Blood. 2011 Feb 17;117(7):2200-10. doi: 10.1182/blood-2010-06-288498. Epub 2010 Nov 15.

46.

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors.

Andersen RS, Sørensen RB, Ritter C, Svane IM, Becker JC, thor Straten P, Andersen MH.

Cancer Immunol Immunother. 2011 Feb;60(2):227-34. doi: 10.1007/s00262-010-0933-y. Epub 2010 Oct 28.

47.

Therapeutic cancer vaccines in combination with conventional therapy.

Andersen MH, Junker N, Ellebaek E, Svane IM, Thor Straten P.

J Biomed Biotechnol. 2010;2010:237623. doi: 10.1155/2010/237623. Epub 2010 Jun 29. Review.

48.

Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.

Berntsen A, Brimnes MK, thor Straten P, Svane IM.

J Immunother. 2010 May;33(4):425-34. doi: 10.1097/CJI.0b013e3181cd870f.

PMID:
20386464
49.

Comment on "Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression".

Sørensen RB, thor Straten P, Andersen MH.

J Immunol. 2009 Nov 15;183(10):6040. doi: 10.4049/jimmunol.0990093. No abstract available.

50.

The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.

Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, thor Straten P, Andersen MH.

PLoS One. 2009 Sep 7;4(9):e6910. doi: 10.1371/journal.pone.0006910.

Supplemental Content

Loading ...
Support Center